<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03040635</url>
  </required_header>
  <id_info>
    <org_study_id>NP39625</org_study_id>
    <nct_id>NCT03040635</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7034067 in Healthy Japanese Participants</brief_title>
  <official_title>An Investigator/Subject Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of RO7034067 in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled study to investigate the safety, tolerability,
      pharmacokinetics and pharmacodynamics of single oral doses of RO7034067 in healthy Japanese
      participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2017</start_date>
  <completion_date type="Actual">October 2, 2017</completion_date>
  <primary_completion_date type="Actual">October 2, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of RO7034067</measure>
    <time_frame>Pre-dose (0 hour [hr]), 0.5, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168, 264 hr postdose from Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of RO7034067</measure>
    <time_frame>Pre-dose (0 hr), 0.5, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168, 264 hr postdose from Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve up to the Last Measurable Concentration (AUClast) of RO7034067</measure>
    <time_frame>Pre-dose (0 hr), 0.5, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168, 264 hr postdose from Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of RO7034067</measure>
    <time_frame>Pre-dose (0 hr), 0.5, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168, 264 hr postdose from Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve up to Time t (AUC0-t) of RO7034067</measure>
    <time_frame>Pre-dose (0 hr), 0.5, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168, 264 hr postdose from Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-Life (t1/2) of RO7034067</measure>
    <time_frame>Pre-dose (0 hr), 0.5, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168, 264 hr postdose from Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of RO7034067</measure>
    <time_frame>Pre-dose (0 hr), 0.5, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168, 264 hr postdose from Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Volume of Distribution (Vz/F) of RO7034067</measure>
    <time_frame>Pre-dose (0 hr), 0.5, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168, 264 hr postdose from Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Amount Excreted Unchanged into Urine (Ae) of RO7034067</measure>
    <time_frame>Pre-dose (0 hr), and 5 urine samples at different time-ranges postdose (0-6 hr, 6-12 hr, 12-24 hr, 24-48 hr, and 48-72 hr)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLR) of RO7034067</measure>
    <time_frame>Pre-dose (0 hr), and 5 urine samples at different time-ranges postdose (0-6 hr, 6-12 hr, 12-24 hr, 24-48 hr, and 48-72 hr)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of Dose Excreted Unchanged Renally (Fe) of RO7034067</measure>
    <time_frame>Pre-dose (0 hr), and 5 urine samples at different time-ranges postdose (0-6 hr, 6-12 hr, 12-24 hr, 24-48 hr, and 48-72 hr)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Splicing Modifications of Survival of Motor Neuron (SMN) Messenger Ribonucleic Acids (mRNAs), Including SMN1, SMN2 Full Length (FL), and SMNdelta7 mRNA in Blood In Vivo</measure>
    <time_frame>Days -1, 1, 2, 3, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in mRNA Levels of Paired Box (PAX) Genes in Blood</measure>
    <time_frame>Days -1, 1, 2, 3, 4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SMN Protein Levels in Blood</measure>
    <time_frame>Day -1, follow-up visit (Day 21)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>RO7034067 '2' Milligrams (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 2 mg RO7034067 will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7034067 '6' mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 6 mg RO7034067 will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7034067 '12' mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 12 mg RO7034067 will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7034067</intervention_name>
    <description>Single oral doses of RO7034067 will be administered on Day 1.</description>
    <arm_group_label>RO7034067 '2' Milligrams (mg)</arm_group_label>
    <arm_group_label>RO7034067 '6' mg</arm_group_label>
    <arm_group_label>RO7034067 '12' mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single oral doses of RO7034067 matching placebo will be administered on Day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants of Japanese origin, with Japanese parents (for the provisional Caucasian
             cohort, participants must be male or female Caucasians with 4 Caucasian grand-parents)

          -  Healthy participants. Healthy status is defined by the absence of evidence of any
             active or chronic disease following a detailed medical and surgical history, a
             complete physical examination including ophthalmological examination, vital signs,
             12-lead electrocardiogram (ECG), hematology, blood chemistry, serology and urinalysis

          -  A body mass index (BMI) between 18 to 30 kilograms per square meter (kg/m^2) inclusive

          -  Male participants must agree to use a barrier method of contraception from dosing
             until completion of the study and for 4 months thereafter

          -  Female participants must be either surgically sterile or post-menopausal

        Exclusion Criteria:

          -  Medical history of cardiovascular disease, renal disease, liver disease, digestive
             system disease, blood dyscrasia, immunologic disease, diseases of the nervous system,
             endocrine disease, metabolic disease, lung disease, or with anamnesis and obstacles in
             kidney, liver, or cardiopulmonary function

          -  Participants with any clinically significant eye pathology

          -  Laboratory test (hematology, biochemistry, physical examination or vital signs) values
             outside the institutional normal range and rated as clinically significant abnormal at
             screening

          -  Any clinically significant abnormalities in ECG at screening

          -  Inherited long QT syndrome or known family history of arrhythmia

          -  Systolic blood pressure (SBP) higher than 140 millimeters of mercury (mmHg) or below
             90 mmHg, and/or diastolic blood pressure (DBP) higher than 90 mmHg or below 50 mmHg in
             the supine position, as assessed at screening

          -  Positive result for human immunodeficiency virus (HIV) antigen and antibody, hepatitis
             B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody at screening

          -  Donation or loss of blood over 500 milliliters (mL) within three months prior to
             screening

          -  History of smoking more than 10 cigarettes a day. Participants who have quit smoking
             or who have reduced their daily cigarette smoking to 10 or less for more than one
             month prior to screening are allowed

          -  Daily consumption of food or drink containing a large amount of methylxanthine
             (caffeine, theophylline, theobromine)

          -  Present or past history of substance addiction, dependence or abuse, such as abuse of
             drugs or alcohol

          -  Concomitant or previous participation in any clinical trial either within 90 days or 5
             half-lives of the investigational drug, whichever is longer, before administration of
             study drug in this study

          -  Use of prescribed medications which have systemic exposure within one week before
             enrolment

          -  Use of any concomitant drug during the study (including over-the-counter medication
             and medications used in dentistry)

          -  Inability to meet the study requirements in the opinion of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

